Arecor Therapeutics
Arecor Therapeutics is a biopharmaceutical company developing enhanced formulations of existing therapeutic products for diabetes and cardiometabolic diseases.
Its proprietary formulation technology improves stability, concentration and delivery profiles for biologics and peptides, supporting both in-house programmes and partnered development with pharmaceutical and medtech companies.
One formulated product is on the market and generating royalties.
The lead proprietary pipeline includes an ultra-concentrated rapid-acting insulin and an oral GLP-1 programme for obesity and type 2 diabetes.
Latest News
Arecor Therapeutics Raises £5m in Placing to Extend Cash Runway to December 2027
Arecor Therapeutics has raised approximately £5.0 million through a placing of 7,352,941 new shares at 68 pence each with institutional and other professional investors. The proceeds extend its cash runway to December 2027 and fund its insulin development programme while it continues advanced-stage negotiations with multiple insulin pump companies.
Arecor Therapeutics Publishes Peer-Reviewed AT278 Trial Results
Arecor Therapeutics has published full results from its AT278-104 trial in the peer-reviewed journal Diabetes, Obesity & Metabolism, the first complete peer-reviewed data set for its ultra-concentrated (500U/mL) insulin aspart. AT278 was absorbed faster than both standard-strength insulin aspart and U500 human regular insulin, and crucially kept its rapid onset regardless of patient BMI, addressing a weakness that has limited earlier concentrated insulins and supporting Arecor's push to pair AT278 with automated insulin delivery systems.